Customize your JAMA Network experience by selecting one or more topics from the list below.
Given the variable nature of prostate cancer and the multiple treatment options suggested by the National Comprehensive Cancer Network guidelines for low-, intermediate-, and high-risk prostate cancer,1 discerning what factors influence treatment choice is essential for understanding how to optimize the appropriate use of treatments and cancer outcomes. In the early 1990s, the pendulum had swung following the introduction of widespread prostate-specific antigen (PSA) screening and the annual number of radical prostatectomy procedures doubled, while “watchful waiting” became an approach for caring for older patients and men with comorbid illnesses. A comprehensive update on patterns of care for older men (>65 years) in the mid 2000s, where attitudes regarding expectant management for prostate cancer, is welcome and needed.2
Prasad SM, Sartor AO, Bennett CL. Population-Based Assessment of Determining Treatments for Prostate Cancer. JAMA Oncol. 2015;1(1):67–68. doi:10.1001/jamaoncol.2014.183
Create a personal account or sign in to: